Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

ConclusionsThe addition of bevacizumab to erlotinib prolonged progression-free survival inEGFR mutation-positive NSCLC. Follow-up safety data were consistent with the known safety profiles of both erlotinib and bevacizumab in NSCLC; this combination appeared to be manageable, and treatment was well tolerated.JapicCTI-111390.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research

Related Links:

AM Abstract Adoptive transfer of T cells transgenic for tumor-reactive T-cell receptors (TCR) is an attractive immunotherapeutic approach. However, clinical translation is so far limited due to challenges in the identification of suitable target antigens as well as TCRs that are concurrent safe and efficient. Definition of key characteristics relevant for effective and specific tumor rejection is essential to improve current TCR-based adoptive T-cell immunotherapies. We here characterized in-depth two TCRs derived from the human leukocyte antigen (HLA)-mismatched allogeneic repertoire targeting two different myel...
Source: Nuklearmedizin - Category: Radiology Authors: Tags: Front Immunol Source Type: research
ConclusionsThe study recommend the development of a model to guide the integration of breast cancer prevention and early detection into palliative care
Source: International Journal of Africa Nursing Sciences - Category: African Health Source Type: research
Advances in nanophotonics could one day lead to new treatments for cancer, mental disorders More at https://www.nsf.gov/discoveries/disc_summ.jsp?cntn_id=298904&WT.mc_id=USNSF_1 This is a Research News item.
Source: NSF Discoveries - Category: Science Source Type: research
Publication date: Available online 18 July 2019Source: The American Journal of SurgeryAuthor(s): Brigid K. Killelea, Emily J. Gallagher, Sheldon M. Feldman, Elisa Port, Tari King, Susan K. Boolbol, Rebeca Franco, Kezhen Fei, Derek Le Roith, Nina A. BickellAbstractIntroductionAlthough breast cancer incidence is higher among white women, black women are more likely to have aggressive tumors with less favorable histology, and to have a worse prognosis. Obesity and alcohol consumption have been identified as two modifiable risk factors for breast cancer, while physical activity may offer protection. Little however is known abo...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
Publication date: Available online 18 July 2019Source: The American Journal of SurgeryAuthor(s): Laura H. Rosenberger, Samantha M. Thomas, Jennifer K. Plichta, Oluwadamilola M. Fayanju, Terry Hyslop, Rachel A. Greenup, E. Shelley HwangAbstractBackgroundSentinel lymph node biopsy has supplanted axillary lymph node dissection (ALND) in clinically node-negative breast cancer and select node-positive disease. We hypothesized a decreasing rate of both ALND and resident exposure over time.MethodsWe identified women with clinical Stage I-III breast cancer in the National Cancer Data Base (2004-2014). Adjusted multivariate logisti...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
This study describes the treatment patterns, effectiveness, and safety profile of Pem-Pt + Bev in patients with NS-NSCLC in China in clinical practice. METHODS: Data from eligible patients with advanced NS-NSCLC who received Pem-Pt with (136 patients) or without (97 patients) bevacizumab from January 2012 to March 2017 were retrospectively evaluated. The effectiveness outcomes included the assessment of progression-free survival (PFS) and objective response rate (ORR) in the overall population, the percentage of patients with pleural effusion or brain metastasis, as well as the percentage of patients receivi...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research
Authors: Han S, Hong Y, Liu T, Wu N, Ye Z Abstract Objectives: To investigate the efficacy and safety of Bevacizumab (Bev) used in combination with paclitaxel and carboplatin (PC), compared with PC alone in patients with advanced non-small-cell lung cancer (NSCLC). Materials and Methods: We searched the PubMed, EMBASE, Cochrane Central Register of Controlled Trials and Chinese Biomedical Literature electronic databases, to identify randomized controlled trials of PC plus Bev versus PC alone for the treatment of NSCLC. The meta-analysis was performed using Reviewer Manager Version 5.3 software provided by the Co...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONSAll 3 regimens were feasible for patients with advanced NSCLC and an ECOG performance status of 2. The addition of bevacizumab to pemetrexed increased the overall response rate. The efficacy of pemetrexed/carboplatin/bevacizumab (median PFS, 4.8 months) approached the prespecified study PFS goal of 5 months. Larger studies will be necessary to define the role of bevacizumab in addition to standard pemetrexed and carboplatin in this population. Cancer 2018. © 2018 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Authors: Losanno T, Gridelli C Abstract Introduction - Lung cancer still represents the leading cause of death for cancer. About the 70% of diagnosis are in advanced-stage. Non-small-cell lung cancer (NSCLC) represents the 85% of all diagnosed lung cancers and non-squamous histology represents the 40% of all NSCLC. First-line therapies increase survival, control symptoms and improve quality of life, compared with best supportive care. It is crucial to choose a treatment with a low impact on patient's life considering the related toxicities. Areas covered - Adverse events (AEs) of first-line therapies for non-squamo...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Vascular endothelial growth factor (VEGF) plays the most important role in regulating tumor-related angiogenesis and is often highly expressed in human cancers making it a preferred target for antitumor therapy [1,2]. With the introduction of VEGF inhibitors for cancer treatment, new class-specific adverse events (AEs) for these drugs have been observed, including perforations, bleeding, thromboembolic events, hypertension, and proteinuria [3,4]. Skin-related AEs are also often associated with the anti-VEGF small-molecule tyrosine kinase inhibitors sorafenib and sunitinib although these effects are not related directly to ...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Avastin | Bleeding | Cancer | Cancer & Oncology | Drugs & Pharmacology | Hypertension | Lung Cancer | Non-Small Cell Lung Cancer | Proteinuria | Study | Tarceva